pneumothoraces. This method would definitely add a revolutionary step in management of large and severe spontaneous pneumothoraces with persistent pleural airleaks. It may help avoid major thoracic surgical procedures and subsequent postoperative morbidity, at least in a group of patients who are not suitable candidates for thoracotomy.
Should the technique be called fibrin glue pleurodesis?
An adequate coverage of airleak by fibrin glue closes the source of pneumothorax. Once the site of airleak is blocked with fibrin glue, the lung will have a chance to expand. Does the glue produce sufficient inflammation to cause pleural symphysis, so that it can be called pleurodesis? Lack of inflammation might be responsible for minimal pleural thickening associated with this procedure. 2. The relationship between failure of first and subsequent infusions of fibrin glue and the extent of underlying lung disease is not discussed by the authors. Did the presence of pulmonary fibrosis prevent complete expansion of lung, even after adequate glue application? Is there any contraindication to this procedure, where the lung is not expected to expand because of severe underlying lung disease, or when thick pleural rind has already been developed? 3. Is it possible to apply fibrin glue to bronchial stump at the time of the pneumonectomy/lobectomy, so that risk of postoperative airleaks may be lowered and reduce the incidence of such pneumothoraces? 4. I would also like to know the author's experience with fibrin glue in patients with pyopneumothorax or hydropneumothorax with bronchopleural fistula because of bacterial or mycobacterial infections in the underlying lung. Once the fluid is drained by chest tube, can it be applied to pleural airleaks in the presence of infection in the lung? 5. According to MEDLINE, references 27 and 29 are incorrectly cited on the reference list. 
The Loss of Endothelium-Dependent Vascular Tone Control in Systemic Sclerosis
To the Editor:
Systemic sclerosis (SSc) is characterized by the widespread involvement of the microvasculature and by severe damage to the endothelium 1 as well as by the modification of vascular tone control. 2 The endothelium-dependent control of vascular tone is one of the main functions that is jeopardized during endothelial injury.
The work of Cailes et al 3 is a precious report showing the impairment of the endothelium-dependent control of the vascular tone in the lungs of SSc patients. Actually, our group was the first to report in 1990 such a result in the acral circulation of patients with SSc. We demonstrated that during the evolution of the disease, the endothelium-dependent vasodilation was impaired either when the level of von Willebrand factor, the marker of endothelial injury, was normal in the early phase of the disease or when it was greatly raised in the advanced phase of the disease. 4 The failure of endothelial-dependent regulation of vasodilation then was confirmed in the acral circulation by Bedarida et al 5 and in the skin circulation by La Civita et al. 6 Recent data indirectly also demonstrate a defective vasodilating ability in the renal vasculature of SSc patients who have no sign of kidney involvement during standard clinical evaluations. 7 In fact, we have found that the renal functional reserve, or the ability of the kidney to increase its glomerular filtration rate (GFR) and effective plasma flow (ERPF) when challenged with a protein or an amino acid load is blunted in patients with SSc. During the amino acid load test, GFR, ERPF, and total renal vascular resistance (TRVR) remained substantially unchanged in 20 SSc patients ([mean ϮSD] GFR, Ϫ2 Ϯ 13.1 mL/min; ERPF, Ϫ4.1 Ϯ 62.5 mL/min; and TRVR, 662 Ϯ 2,215 dyne ⅐ s Ϫ1 ⅐ cm Ϫ5 ), whereas 10 healthy control subjects showed the expected significant changes in these parameters (GFR, 30.0 Ϯ 13.3 mL/min [p Ͻ 0.001]; ERPF, 111.6 Ϯ 39.6 mL/min
. Only five of 20 SSc patients had a GFR increase comparable to that of the control subjects (Ն 10%). The defective response was not dependent on the duration or the clinical subset of the disease, and it could be observed early in the course of the illness (median time interval from diagnosis, 18 months).
There is general agreement that the activation of the renal functional reserve depends on preglomerular vasodilation, and nitric oxide has been indicated as a major mediator of the phenomenon. Thus, the defective renal functional response to the protein load reflects an impaired endothelial-dependent vasodilation in the renal vasculature. 7 In conclusion, the analysis of the literature of the last decade shows that in SSc, the endothelium-dependent control of the vascular tone is profoundly deranged in different organs. This evidence strongly suggests that the pivotal aim of the physician, in particular in the early phase of the disease, is the protection of the endothelium in order to keep its function at a steady level. This might allow an adequate tissular blood flow, thus avoiding the damage due to ischemia and reperfusion, as well as the further breakdown of vessel patency. 
Clarification of Sleep Study Procedures
I attended the 14th Associated Professional Sleep Societies annual meeting, where Victor Hoffstein, MD, PhD, presented his article on the variable mandibular advancement appliance (MAA). 1 On page 1512, the "Investigations" section, third paragraph, he states, "After the appliance was manufactured and final adjustments completed. . .polysomnography was performed with the appliance." I asked Dr. Hoffstein if the mandibular portion of the MAA was further advanced at the time of polysomnogram (PSG). Dr. Hoffstein's co-author, Jeffrey Pancer, DDS, said each of the various sleep laboratories in the investigation had received a letter in which the sleep technicians were instructed to "adjust [the mandibular portion of the MAA] gently. . .if the patient is snoring during the night. . .until snoring ceases or, if the patient is experiencing obstructive apnea,. . .until no apneas are occurring" (Fig 1) . Dr. Pancer said the sleep laboratory technicians followed these instructions inconsistently and that no records were kept of which MAAs were so adjusted.
In fact, the alteration of the appliance position by the technician at the time of the second PSG did not follow the article's prescribed procedure. Rather than evaluating the performance of the oral appliance, the second PSG seems to have been an experiment in manipulating the MAA to its most effective position. Other publications in this field have used a patient/ dentist-determined jaw position for follow-up, which makes the outcome data of this report impossible to compare with earlier published works. Furthermore, the data as presented may mislead the reader to believe that the particular MAA used (the Thornton anterior positioner [TAP]) may be more effective, especially in severe obstructive sleep apnea patients, than traditional therapeutic follow-up PSGs would indicate.
With no record of which MAA was further advanced, it is difficult to determine the following:
1. Which or how many appliances required additional advancement beyond the position determined by the patient ("The final protrusion of the jaw was not recorded because the patients were instructed how to change the amount of protrusion depending on symptoms and did so regularly at home"). 1 2. Which appliances, advanced at the time of PSG, were later retracted by the patient to a more comfortable (and possibly less effective) position after the experimental PSG. 3. Whether the mandibular position was less effective for the 44% of patients for whom no second PSG was completed. The reader has no indication of the percentage of MAAs that required additional advancement to maximize their effect.
The adjustment of the MAA at the time of the second PSG, with the specific intent of improving snoring and apnea/hypopnea index, cannot constitute an evaluation of the effectiveness of the appliance as positioned by the patient or dentist. Rather, the second PSG must be viewed as an experimental process that looks at the titratability of this MAA. If the PSG purporting to assess outcome was in fact experimental, the accuracy of the study must remain in question until another therapeutic follow-up PSG is conducted on all patients whose MAAs were adjusted at the time of the second PSG, permitting comparison of the results of the TAP appliance with the existing literature.
To clear up any possible confusion in either the dental or medical sleep fields, and to clarify further data summarized in this study, I request that this letter be published in CHEST at your earliest convenience.
B. Gail Demko, DMD Newton Highlands, MA
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